Clinical characteristics of 164 AML patients studied
| Characteristics . | All patients, (N = 164) . | No post-CR CH, (N = 85) (% or range) . | Post-CR CH, (N = 79) (% or range) . | P* . |
|---|---|---|---|---|
| Sex | ||||
| Female | 80 (49) | 38 (45) | 42 (53) | .348 |
| Age | 53 | 47 | 57 | <.001 |
| (17-85) | (17-81) | (23-85) | ||
| AML subtype | ||||
| De novo | 129 (79) | 71 (84) | 58 (73) | .162 |
| Secondary | 14 (9) | 4 (5) | 10 (13) | |
| Therapy-related | 21 (13) | 10 (12) | 11 (14) | |
| ELN classification | ||||
| Favorable | 36 (22) | 21 (25) | 15 (19) | .806 |
| Intermediate | 65 (40) | 34 (40) | 31 (39) | |
| Adverse | 61 (37) | 29 (34) | 32 (41) | |
| Induction therapy | ||||
| High intensity | 126 (77) | 74 (87) | 52 (66) | .04 |
| Low intensity | 38 (23) | 11 (13) | 27 (34) | |
| Allo-SCT in −1st CR | ||||
| No | 101 (62) | 56 (66) | 45 (57) | .246 |
| Yes | 63 (38) | 29 (34) | 34 (43) |
| Characteristics . | All patients, (N = 164) . | No post-CR CH, (N = 85) (% or range) . | Post-CR CH, (N = 79) (% or range) . | P* . |
|---|---|---|---|---|
| Sex | ||||
| Female | 80 (49) | 38 (45) | 42 (53) | .348 |
| Age | 53 | 47 | 57 | <.001 |
| (17-85) | (17-81) | (23-85) | ||
| AML subtype | ||||
| De novo | 129 (79) | 71 (84) | 58 (73) | .162 |
| Secondary | 14 (9) | 4 (5) | 10 (13) | |
| Therapy-related | 21 (13) | 10 (12) | 11 (14) | |
| ELN classification | ||||
| Favorable | 36 (22) | 21 (25) | 15 (19) | .806 |
| Intermediate | 65 (40) | 34 (40) | 31 (39) | |
| Adverse | 61 (37) | 29 (34) | 32 (41) | |
| Induction therapy | ||||
| High intensity | 126 (77) | 74 (87) | 52 (66) | .04 |
| Low intensity | 38 (23) | 11 (13) | 27 (34) | |
| Allo-SCT in −1st CR | ||||
| No | 101 (62) | 56 (66) | 45 (57) | .246 |
| Yes | 63 (38) | 29 (34) | 34 (43) |
Clinical characteristics were compared between patients with and without post-CR CH.
Differences in characteristics were tested by Fisher exact test.